Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage
Conclusion
These results indicated that Lenvatinib inhibited VEGF- and FGF-driven angiogenesis and showed a broad spectrum of antitumor activity with a wide therapeutic window. MVD and pericyte-coverage of tumor vasculature might be biomarkers and suggest cases that would respond for lenvatinib therapy.
Source: Vascular Cell - Category: Cytology Source Type: research
More News: Cancer | Cancer & Oncology | Cytology | Gastric (Stomach) Cancer | Kidney Cancer | Liver | Oral Cancer | Pancreas | Pancreatic Cancer | Study | Urology & Nephrology